Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: Oxadiazolyl ketones

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4167-4172

  Koo, Ki Dong ^a   Kim, Min Jung ^a   Kim, Sungsub ^a   Kim, Kyoung Hee ^a   Hong, Sang Yong ^a   Hur, Gwong Cheung ^a   Yim, Hyeon Joo ^a   Kim, Geun Tae ^a   Han, Hee Oon ^a   Kwon, O Hwan ^a   Kwon, Tae Sik ^a   Koh, Jong Sung ^a   Lee, Chang Seok ^a  

^a LG Chemical Ltd   (South Korea)

Author keywords

DPPIV inhibitors; Oxadiazolyl ketones

Indexed keywords

1,2,4 OXADIAZOLYL KETONE DERIVATIVE; 1,3,4 OXADIAZOLYL KETONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIGENS, CD26; CRYSTALLOGRAPHY, X-RAY; DOGS; HAPLORHINI; KETONES; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34347369279     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.046     Document Type: Article

References (21)

1. Zander M., Madsbad S., Madsen J.L., and Holst J.J. The Lancet 359 (2002) 824
2. Knudsen L.B. J. Med. Chem. 47 (2004) 4128
3. Gautier J.F., Fetita S., Sobngwi E., and Salaun-Martin C. Diabetes Metab. 31 (2005) 233
4. Drucker D.J. Diabetes 47 (1998) 159
5. Kiffer T.J., McIntosh C.H.S., and Pederson T.A. Endocrinology 136 (1995) 3585
6. Mentlein R., Gallwitz B., and Schmidt W.E. Eur. J. Biochem. 214 (1993) 829
7. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M., Patel R.A., Petrov A., Scapin G., Patel S.B., Roy R.S., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. J. Med. Chem. 48 (2005) 141
8. Weber A.E. J. Med. Chem. 47 (2004) 4135
9. Villhauer E.B., Coppola G.M., and Hughes T.E. Ann. Rep. Med. Chem. 36 (2001) 191
10. Drucker D.J. Expert Opin. Investig. Drugs 12 (2003) 87
11. Wiedeman P.E., and Trevillyan J.M. Curr. Opin. Investig. Drugs 4 (2003) 412
12. Deacon C.F., Ahre'n B., and Holst J. J. Expert Opin. Investig. Drugs 13 (2004) 1091
13. Augustyns K., Veken P.V.V., and Haemers A. Expert Opin. Ther. Patents 15 (2005) 1387
14. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E.J. Med. Chem. 46 (2003) 2774
15. McIntyre J.A., and Castan' er J. Drugs Future 29 (2004) 887
16. Eduards P.D., Wolannin D.J., Andisik D.W., and Davis M.W. J. Med. Chem. 38 (1995) 76
17. Ferraris D., Ko Y.-S., Calvin D., Chiou T., Lautar S., Thomas B., Wozniak K., Rojas C., Kalish V., and Belyakov S. Bioorg. Med. Chem. Lett. 14 (2004) 5579
18. Gerenal synthesis of 1,2,4-oxadiazole; Tracy, L. D; Theodore, J. N; Diane, C; Denise, E. P; John, A. P. J. Bioorg. Med. Chem. Lett. 1999, 9, 209.
19. Each animal received its oral dosing solution at time 0 h. Vehicle was water. Blood samples were collected through tail vein just before (time 0) and 1, 3, 6, 12, 24, and 48 h after dosing. Data are means ± SE (n = 3).
20. Oefner C., D'Arcy A., Sweeney A.M., Pierau S., Gardiner R., and Dale G.E. Acta Cryst. D59 (2003) 1206
21. The coordinate will be deposited in the Protein Data Bank: PDB ID.